"Dacarbazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
| Descriptor ID |
D003606
|
| MeSH Number(s) |
D02.925.200 D03.383.129.308.240
|
| Concept/Terms |
Dacarbazine- Dacarbazine
- Dimethyl Imidazole Carboxamide
- Carboxamide, Dimethyl Imidazole
- Imidazole Carboxamide, Dimethyl
- DTIC
- ICDT
- Decarbazine
- 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
- DIC
- Dimethyl Triazeno Imidazole Carboxamide
|
Below are MeSH descriptors whose meaning is more general than "Dacarbazine".
Below are MeSH descriptors whose meaning is more specific than "Dacarbazine".
This graph shows the total number of publications written about "Dacarbazine" by people in this website by year, and whether "Dacarbazine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 5 | 5 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 3 | 3 |
| 2000 | 4 | 1 | 5 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 8 | 9 |
| 2003 | 6 | 1 | 7 |
| 2004 | 7 | 0 | 7 |
| 2005 | 4 | 2 | 6 |
| 2006 | 5 | 9 | 14 |
| 2007 | 6 | 6 | 12 |
| 2008 | 3 | 19 | 22 |
| 2009 | 7 | 6 | 13 |
| 2010 | 7 | 8 | 15 |
| 2011 | 6 | 9 | 15 |
| 2012 | 6 | 5 | 11 |
| 2013 | 5 | 11 | 16 |
| 2014 | 7 | 12 | 19 |
| 2015 | 13 | 6 | 19 |
| 2016 | 6 | 9 | 15 |
| 2017 | 9 | 9 | 18 |
| 2018 | 1 | 7 | 8 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 6 | 6 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dacarbazine" by people in Profiles.
-
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 Oct 17; 391(15):1379-1389.
-
Temozolomide use in elderly patients with MGMT promoter unmethylated glioblastoma: Is it finally time to dismount a dead horse? Neuro Oncol. 2024 Oct 03; 26(10):1876-1877.
-
Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide. J Med Chem. 2024 02 22; 67(4):2425-2437.
-
Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective. JCO Oncol Pract. 2023 10; 19(10):860-870.
-
Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. Leuk Lymphoma. 2023 05; 64(5):1017-1025.
-
Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States. Clin Lymphoma Myeloma Leuk. 2023 07; 23(7):527-534.
-
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair. Adv Sci (Weinh). 2023 01; 10(3):e2205529.
-
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023 03 01; 41(7):1359-1369.
-
Older patients (aged =60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 05 01; 107(5):1086-1094.
-
Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. Pediatr Blood Cancer. 2022 05; 69(5):e29601.